AbbVie received positive EU regulatory opinions for Boey (glabellar lines) and MAVIRET (acute hepatitis C), with final decisions expected soon. It presented strong IBD data for Skyrizi and Rinvoq, and will showcase oncology data at ASCO. These developments, alongside its high-yield dividend, position AbbVie as a low-risk, long-term stock with expanding pipelines in aesthetics, antivirals, immunology, and oncology.